Sangamo Therapeutics (SGMO) to Release Quarterly Earnings on Tuesday

Sangamo Therapeutics (NASDAQ:SGMO) will likely be posting its Q3 2025 results before the market opens on Tuesday, November 11th. Analysts expect the company to announce earnings of ($0.03) per share and revenue of $34.40 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, November 6, 2025 at 8:30 AM ET.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.01). Sangamo Therapeutics had a negative net margin of 77.48% and a negative return on equity of 293.05%. The firm had revenue of $18.31 million during the quarter, compared to analyst estimates of $31.68 million. On average, analysts expect Sangamo Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Sangamo Therapeutics Trading Down 0.7%

NASDAQ SGMO traded down $0.00 during trading hours on Tuesday, reaching $0.57. 864,843 shares of the company traded hands, compared to its average volume of 5,776,306. The company has a 50 day moving average of $0.60 and a two-hundred day moving average of $0.57. The stock has a market capitalization of $173.18 million, a PE ratio of -1.98 and a beta of 1.22. Sangamo Therapeutics has a 12 month low of $0.41 and a 12 month high of $3.18.

Analysts Set New Price Targets

SGMO has been the subject of several research reports. Wall Street Zen upgraded Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 16th. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Sangamo Therapeutics in a research note on Thursday, September 4th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sangamo Therapeutics in a report on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Sangamo Therapeutics has an average rating of “Hold” and a consensus price target of $4.50.

Hedge Funds Weigh In On Sangamo Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Wasatch Advisors LP lifted its stake in shares of Sangamo Therapeutics by 17.7% in the 2nd quarter. Wasatch Advisors LP now owns 8,084,419 shares of the biopharmaceutical company’s stock worth $4,376,000 after acquiring an additional 1,215,653 shares during the period. Geode Capital Management LLC boosted its position in Sangamo Therapeutics by 2.1% during the second quarter. Geode Capital Management LLC now owns 2,332,279 shares of the biopharmaceutical company’s stock valued at $1,263,000 after purchasing an additional 48,829 shares during the last quarter. Invesco Ltd. increased its position in Sangamo Therapeutics by 40.6% in the 2nd quarter. Invesco Ltd. now owns 680,452 shares of the biopharmaceutical company’s stock worth $368,000 after purchasing an additional 196,558 shares during the last quarter. Engineers Gate Manager LP raised its stake in shares of Sangamo Therapeutics by 101.7% during the 2nd quarter. Engineers Gate Manager LP now owns 87,425 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 44,078 shares in the last quarter. Finally, XTX Topco Ltd acquired a new stake in shares of Sangamo Therapeutics in the second quarter worth about $41,000. Institutional investors own 56.92% of the company’s stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.